| scholarly article | Q13442814 |
| P50 | author | Gene G Olinger | Q37614369 |
| Wendy Maury | Q56808440 | ||
| Ashley L Cooney | Q57286378 | ||
| John M Dye | Q62478445 | ||
| Katherine Perschbacher | Q86391438 | ||
| P2093 | author name string | Nicholas J Lennemann | |
| Andrew S Herbert | |||
| Julia Biggins | |||
| Bethany Rhein | |||
| Rachel Brouillette | |||
| Patrick Ten Eyck | |||
| Catherine L Miller-Hunt | |||
| Russell A Bakken | |||
| P2860 | cites work | Current ebola vaccines | Q21534720 |
| Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses | Q21562420 | ||
| Tyrosine kinase receptor Axl enhances entry of Zaire ebolavirus without direct interactions with the viral glycoprotein | Q24300740 | ||
| T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus | Q24301153 | ||
| The Tyro3 receptor kinase Axl enhances macropinocytosis of Zaire ebolavirus | Q24305409 | ||
| Clinical development of Ebola vaccines | Q26775792 | ||
| Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor | Q27651112 | ||
| Techniques and tactics used in determining the structure of the trimericebolavirusglycoprotein | Q27658238 | ||
| Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1 | Q27679280 | ||
| Protein structure prediction on the Web: a case study using the Phyre server | Q27860664 | ||
| Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!) | Q28051937 | ||
| Cell-targeting antibodies in immunity to Ebola | Q28068972 | ||
| Development of a preventive vaccine for Ebola virus infection in primates | Q28140401 | ||
| Antibody neutralization and escape by HIV-1 | Q29547345 | ||
| Glycans on influenza hemagglutinin affect receptor binding and immune response | Q30381577 | ||
| Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus | Q30724121 | ||
| Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys | Q33269796 | ||
| Structure of the Ebola virus glycoprotein spike within the virion envelope at 11 Å resolution | Q33551748 | ||
| Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species | Q33587515 | ||
| Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. | Q33768646 | ||
| On a path to accelerate access to Ebola vaccines: The WHO's research and development efforts during the 2014-2016 Ebola epidemic in West Africa | Q33924959 | ||
| Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses | Q33987611 | ||
| A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus | Q34000122 | ||
| A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge. | Q34029668 | ||
| A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector | Q34092753 | ||
| Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates | Q34220503 | ||
| Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions | Q34295953 | ||
| Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells | Q34345308 | ||
| Covalent modifications of the ebola virus glycoprotein | Q34354004 | ||
| Synthetic antibodies with a human framework that protect mice from lethal Sudan ebolavirus challenge | Q34361120 | ||
| Ebola vaccine R&D: Filling the knowledge gaps. | Q34504883 | ||
| Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus | Q34606818 | ||
| Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy | Q34632946 | ||
| Structures of protective antibodies reveal sites of vulnerability on Ebola virus | Q34661120 | ||
| Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice | Q34761889 | ||
| Ebola virus-like particles protect from lethal Ebola virus infection | Q34792924 | ||
| Structural basis for Marburg virus neutralization by a cross-reactive human antibody | Q35132751 | ||
| Controlled viral glycoprotein expression as a safety feature in a bivalent rabies-ebola vaccine | Q35184639 | ||
| Homologous and heterologous protection of nonhuman primates by Ebola and Sudan virus-like particles | Q35202880 | ||
| Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles. | Q35299756 | ||
| Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines | Q35635459 | ||
| Successful topical respiratory tract immunization of primates against Ebola virus | Q35857218 | ||
| The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate | Q35867988 | ||
| Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. | Q35882397 | ||
| A Single-Vector, Single-Injection Trivalent Filovirus Vaccine: Proof of Concept Study in Outbred Guinea Pigs | Q36043219 | ||
| The Role of Conserved N-Linked Glycans on Ebola Virus Glycoprotein 2. | Q36043248 | ||
| N-Glycans on the Nipah virus attachment glycoprotein modulate fusion and viral entry as they protect against antibody neutralization | Q36363882 | ||
| Potential vaccines and post-exposure treatments for filovirus infections | Q36404178 | ||
| Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses | Q36433920 | ||
| Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus. | Q36759944 | ||
| A system for functional analysis of Ebola virus glycoprotein | Q36831630 | ||
| Vesicular stomatitis virus M protein in the nuclei of infected cells | Q36882802 | ||
| Protection against lethal challenge by Ebola virus-like particles produced in insect cells | Q37131622 | ||
| Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters | Q37418736 | ||
| Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule | Q37445501 | ||
| Comprehensive functional analysis of N-linked glycans on Ebola virus GP1. | Q37631492 | ||
| VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications. | Q37714030 | ||
| Recent advances in the development of vaccines for Ebola virus disease | Q38643841 | ||
| Interferon α/β Receptor-Deficient Mice as a Model for Ebola Virus Disease. | Q38878840 | ||
| Ebola virus vaccines - reality or fiction? | Q38881265 | ||
| Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody | Q39683688 | ||
| Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents | Q40042093 | ||
| Single-Vector, Single-Injection Recombinant Vesicular Stomatitis Virus Vaccines Against High-Containment Viruses | Q40109981 | ||
| Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study | Q40153269 | ||
| Update: Ebola virus disease epidemic--West Africa, January 2015. | Q40170735 | ||
| Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents | Q40193887 | ||
| Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies | Q40283103 | ||
| N-glycans on Nipah virus fusion protein protect against neutralization but reduce membrane fusion and viral entry | Q40287207 | ||
| Heterologous boosting with recombinant VSV-846 in BCG-primed mice confers improved protection against Mycobacterium infection | Q40411515 | ||
| Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever | Q40433068 | ||
| Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein | Q40541847 | ||
| Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus | Q40617140 | ||
| A vesicular stomatitis virus-based mucosal vaccine promotes dendritic cell maturation and elicits preferable immune response against coxsackievirus B3 induced viral myocarditis | Q42216061 | ||
| DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge | Q44089592 | ||
| Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections | Q44089771 | ||
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Ebola vaccine | Q3553092 |
| Orthoebolavirus zairense | Q10538943 | ||
| vesicular stomatitis | Q11549084 | ||
| P577 | publication date | 2017-08-10 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Vesicular Stomatitis Virus Pseudotyped with Ebola Virus Glycoprotein Serves as a Protective, Noninfectious Vaccine against Ebola Virus Challenge in Mice | |
| P478 | volume | 91 |
| Q90628383 | Acute Plasmodium Infection Promotes Interferon-Gamma-Dependent Resistance to Ebola Virus Infection |
| Q55306089 | Antibodies to the Glycoprotein GP2 Subunit Cross-React between Old and New World Arenaviruses. |
| Q59352928 | Can Ebola Virus Vaccines Have Universal Immune Correlates of protection? |
| Q64360343 | Pseudovirus rVSVΔG-ZEBOV-GP Infects Neurons in Retina and CNS, Causing Apoptosis and Neurodegeneration in Neonatal Mice |
| Q64229700 | Role of Type I Interferons on Filovirus Pathogenesis |
| Q64073849 | Serologic Prevalence of Ebola Virus in Equatorial Africa |
| Q56558172 | Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection |
| Q90226623 | Viral Vectors for the Induction of Broadly Neutralizing Antibodies against HIV |
| Q92437405 | rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment |
Search more.